Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · September 17, 2023

Allo-HCT Improves Outcomes in Myelodysplastic Syndrome Across High-Risk Genetic Subgroups

Journal of Clinical Oncology


Additional Info

Journal of Clinical Oncology
Allogeneic Hematopoietic Cell Transplantation Improves Outcome in Myelodysplastic Syndrome Across High-Risk Genetic Subgroups: Genetic Analysis of the Blood and Marrow Transplant Clinical Trials Network 1102 Study
J. Clin. Oncol 2023 Aug 22;[EPub Ahead of Print], J Versluis, W Saber, HK Tsai, CJ Gibson, LW Dillon, A Mishra, J McGuirk, RT Maziarz, P Westervelt, P Hegde, D Mukherjee, MJ Martens, B Logan, M Horowitz, CS Hourigan, R Nakamura, C Cutler, RC Lindsley

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading